IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Tan, J. et al.

Confirmation No.:

2636

Serial No.:

10/694,634

Art Unit: 1633

Filed:

October 27, 2003

Examiner: Popa, Ileana

For:

METHODS AND COMPOUNDS FOR

Attorney Docket No.: 12062.105020

DISRUPTION OF CD40/CD40L SIGNALING IN THE TREATMENT

OF ALZHEIMER'S DISEASE

AMENDMENT UNDER 37 C.F.R. § 1.116

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the final Office Action mailed August 8, 2007 ("the Aug. 8 Office Action") please enter the following amendments and consider the following remarks. Applicants submit concurrently herewith (i) a Request for Continued Examination ("RCE") containing authorization for payment of the appropriate fee; (ii) a Petition of Extension of Time for three (3) months for responding to the Office Action, from November 8, 2007 up to and including February 8, 2008; and (iii) an Amendment Fee Transmittal Sheet.

It is believed that there is no fee required for the filing of this response other than those authorized in the RCE and the Petition for Extension of Time submitted concurrently herewith; however, in the event that any additional fee is required, please charge King & Spalding Deposit Account No. 50-3732, order number 12062.105020.

Applicants' Statement of Substance of Interview begins on page 2 of this paper

Amendments to the Claims are reflected in the Listing of Claims, which begin on page 3 of this paper.

Remarks begin on page 7 of this paper.